Inventiva (IVA) Appoints Renée Aguiar-Lucander to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors
June 10, 2025 4:00 PM EDTDaix (France), New York City (New York, United States), June 10, 2025 Inventiva (Euronext Paris and Nasdaq: IVA) (Inventiva or the Company), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Companys Annual General Meeting.
Mark Pruzanski, Chairman of Inventiva: We are thrilled to welcome Renée to the Board at this pivotal moment in Inventivas journey.... More
